Breaking news

Theramir Secures €525,000 To Propel Cancer Therapy To Clinical Phase

by THEFUTURE.TEAM

July 23, 2024

In a significant boost to its pioneering cancer treatment research, Theramir has successfully raised €525,000 in a bridge funding round. This capital injection is poised to support the company’s operations through the latter half of 2025, targeting a critical milestone: the initiation of clinical trials for their innovative therapy, EVmiR.

EVmiR, now patented by the European Patent Office, represents a novel approach in cancer treatment. By utilising extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumours, Theramir aims to target oncoproteins—key regulators of cancer cell growth. This precision method promises fewer side effects compared to traditional treatments such as chemotherapy. The company’s technology has demonstrated efficacy in treating metastatic breast cancer and is now being tested for pancreatic and bladder cancers.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Theramir, co-founded by Marianna Prokopi-Demetriades and Costas Pitsillides in 2016, emerged from a passionate pursuit to find a cure for cancer. Their unique technology capitalises on EVs’ natural ability to transport biological information, essentially turning them into couriers that deliver tumour-suppressive messages via miRNAs. This method requires a detailed genetic profile of the patient to enhance the therapy’s precision and effectiveness, potentially offering prophylactic benefits by identifying genetic markers linked to high-risk conditions.

The latest funding round saw participation from notable investors, including Yannos Palate, a former executive at Eli Lilly, who will join Theramir’s advisory board. His extensive experience in life sciences and pharmaceutical engagement is expected to be instrumental in forging strategic partnerships with major pharmaceutical companies. Other investors include Nicosia-based family office Exerte Partners and finance and corporate lawyer Nancy Erotocritou.

Despite the challenges posed by the limited local life-sciences ecosystem in Cyprus, Theramir has managed to attract significant investor interest, raising €2.5 million in total, including €300,000 in grants. The company’s innovative approach and lower research costs compared to major biotech hubs like Boston or London have contributed to its success.

Looking ahead, Theramir is actively seeking a licensing deal with a major pharmaceutical firm to support the clinical trials, which could span up to seven years. The co-founders are optimistic about expediting the timeline through process efficiencies, projecting a market-ready therapy by 2030. In the interim, they are also exploring new revenue streams, such as using EVmiR to treat chronic malignant wounds through a project named MIRACULOUS, which has secured additional funding.

The Future Forbes Realty Global Properties

Anthropic Launches Claude Fable 5 With New AI Safety Controls

New Model Sets The Bar For AI Safety And Efficiency

Anthropic has launched Claude Fable 5, the latest public version of its Mythos model, expanding access to a system designed for software engineering, knowledge work and computer vision tasks. The company said high-risk requests involving areas such as cybersecurity, biology, chemistry and AI model distillation will be redirected to Claude Opus 4.8, which has been configured with additional safeguards.

Strategic Rollout And Broader Accessibility

Mythos was initially made available to a limited group of partners in April as Anthropic evaluated potential cybersecurity risks associated with the model. Access was expanded last week to hundreds of organisations across 15 countries, primarily those operating critical infrastructure. Claude Fable 5 is now available through Anthropic’s Claude API and usage-based Enterprise plans. Early access has also been included in selected subscription tiers ahead of a broader pricing rollout scheduled for June 23.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Advancing Safety And Industry Standards

Anthropic said the model underwent extensive safety testing before release, including bug bounty programmes and red-team exercises conducted by external organisations. According to the company, more than 1,000 hours of testing did not identify any universal jailbreak vulnerabilities.

A mandatory 30-day data retention policy will apply to all traffic processed by the model, including accounts that previously operated under zero-retention agreements. Anthropic said the measure is intended to improve monitoring and protection against emerging security threats.

Outstanding Performance And Competitive Pricing

Independent evaluations, including testing by analytics company Hex, reported strong performance in complex reasoning and analytical tasks. Companies, including Base44 and Genspark, highlighted improvements in tool use and interface design capabilities. Pricing has been set at $10 per million input tokens and $50 per million output tokens, compared with lower rates for previous models. Some enterprise customers, including Rakuten, said the model’s ability to verify aspects of its own output could help improve efficiency in tasks that require higher levels of accuracy.

Implications For The AI Market

The release comes as Anthropic prepares for a potential public market debut, and competition among leading AI developers continues to intensify. Alongside performance improvements, the company has placed significant emphasis on model safety, reflecting broader industry concerns around misuse, jailbreak attempts and the risks associated with increasingly capable AI systems.